Park S Z, Reardon M J
Division of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Texas 77030, USA.
Curr Opin Cardiol. 2000 Mar;15(2):74-81. doi: 10.1097/00001573-200003000-00002.
The introduction of the Toronto stentless porcine valve (SPV) (St. Jude, Minneapolis, MN), recently approved by the Food and Drug Administration following a 6-year multi-institutional clinical trial from 1991 to 1997, reflects an evolutionary pursuit of an ideal valve substitute, namely, low thrombogenicity, freedom from anticoagulation, durability, easy availability, resistance to infection, and easy implantability. Currently, four different types of valve replacement have been time tested: mechanical valves, cryopreserved aortic homograft, stented heterograft, and pulmonary autograft (Ross procedure), and none of the available valve substitutes meet all the criteria of an ideal valve. The mechanical valve's favorable properties of durability and easy implantability are susceptible to thrombus formation, which requires lifelong anticoagulation. Although the aortic homografts are durable, with low incidence of infection and thrombogenicity, their widespread application has been limited by the lack of availability. The pulmonary autograft, with its native aortic valve properties, has been shunned by some surgeons because it requires a demanding technical expertise in implantation and needs an allograft in the pulmonary position. Stented xenografts are characterized by "off-the-shelf" availability, freedom from anticoagulation, easy implantability, and low incidence of infection. Its major drawback has been its limited durability. Another limitation is its residual transvalvular gradient. A modified version, a stentless xenograft, has been introduced to improve hemodynamic profiles in the hope of subsequent superior structural durability and patient survival. Two valves have been approved by the Food and Drug Administration, the Toronto SPV and the Freestyle valve (Medtronic, Minneapolis, MN). At The Methodist Hospital and the Baylor College of Medicine, the Toronto SPV stentless valve has been our stentless xenograft valve of choice. We therefore review the historical evolution, design advantages, surgical techniques, and clinical outcomes of this valve.
多伦多无支架猪瓣膜(SPV)(圣犹达医疗用品公司,明尼阿波利斯,明尼苏达州)在经历了1991年至1997年的6年多机构临床试验后,最近获得了美国食品药品监督管理局的批准,这反映了对理想瓣膜替代品的不断追求,即低血栓形成性、无需抗凝、耐用性、易于获取、抗感染性以及易于植入性。目前,四种不同类型的瓣膜置换术已经经过了时间的考验:机械瓣膜、低温保存的主动脉同种异体移植物、带支架的异种移植物以及肺动脉自体移植物(罗斯手术),而现有的瓣膜替代品均未完全满足理想瓣膜的所有标准。机械瓣膜具有耐用性和易于植入的良好特性,但易形成血栓,这需要终身抗凝。尽管主动脉同种异体移植物耐用,感染和血栓形成发生率低,但其广泛应用受到供应不足的限制。肺动脉自体移植物具有天然主动脉瓣的特性,但一些外科医生对其避而远之,因为它在植入时需要很高的技术专长,并且在肺动脉位置需要同种异体移植物。带支架的异种移植物的特点是“现货供应”、无需抗凝、易于植入且感染发生率低。其主要缺点是耐用性有限。另一个局限性是其残余跨瓣压差。一种改良版本,即无支架异种移植物,已被引入以改善血流动力学状况,以期随后获得更好的结构耐用性和患者生存率。两种瓣膜已获得美国食品药品监督管理局的批准,即多伦多SPV和自由式瓣膜(美敦力公司,明尼阿波利斯,明尼苏达州)。在卫理公会医院和贝勒医学院,多伦多SPV无支架瓣膜一直是我们首选的无支架异种移植物瓣膜。因此,我们回顾一下这种瓣膜的历史演变、设计优势、手术技术及临床结果。